- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04104139
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (Trifluridine/Tipiracil) With Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer (FIERCE)
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the recommended phase 2 dose of trifluridine and tipiracil hydrochloride (TAS-102) per the proportion of grade 3 or higher adverse events during chemo-radiation therapy (CRT) with concurrent TAS-102 at the maximum tolerated dose by allowing no more than 30% grade 3 or higher adverse events.
SECONDARY OBJECTIVES:
I. Evaluate safety of participants treated with TAS-102 during radiation therapy (RT).
II. Evaluate treatment emergent adverse events (TEAEs) attributable to TAS-102 with RT during fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or capecitabine/oxaliplatin (CAPOX) treatment.
EXPLORATORY OBJECTIVES:
I. To preliminary assess the rates of complete clinical response (cCR) by magnetic resonance imaging (MRI) and by endoscopy after TAS-102 with concurrent CRT.
II. To preliminary assess the rates of cCR by MRI and by endoscopy after treatment with FOLFOX.
III. To preliminary assess the rates of pCR after standard total mesorectal excision (TME).
OUTLINE: This is dose-escalation study of TAS-102.
Patients receive TAS-102 orally (PO) twice daily (BID) Monday-Friday on weeks 1, 3, and 5. Patients also undergo intensity modulated radiotherapy (IMRT) or 3-dimensional conformal radiotherapy (3D-CRT) 5 days per week on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care FOLFOX or CAPOX.
After completion of study treatment, patients are followed for up to a total of 16 weeks (3 months) from end of FOLFOX or CAPOX treatment until rectal cancer surgery or death, whichever occurs first. Participants that opt for a non-surgical option at the end of chemotherapy may be followed for a longer period of time.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: OHSU Knight Cancer Clinical Trials Hotline
- Phone Number: 503-494-1080
- Email: trials@ohsu.edu
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- OHSU Knight Cancer Institute
-
Contact:
- OHSU Knight Cancer Clinical Trials Hotline
- Phone Number: 503-494-1080
- Email: trials@ohsu.edu
-
Contact:
- Emerson Y. Chen, MD
- Email: cheem@ohsu.edu
-
Principal Investigator:
- Charles D. Lopez, MD, PhD
-
Sub-Investigator:
- Emerson Y. Chen, MD
-
Sub-Investigator:
- Nima Nabavizadeh, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All races and ethnic groups will be included
- Histologically confirmed diagnosis of adenocarcinoma of the rectum
- Clinical stage II (T3-4aN0M0) and stage III (T1-4aN1+M0) based on MRI
- Resectable primary rectal tumor at baseline
- No evidence of distant metastases
- No prior pelvic radiation therapy
- No prior chemotherapy or surgery for rectal cancer
- No active infections requiring systemic antibiotic treatment (oral antibiotics are acceptable at the discretion of the treating physician)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Leukocytes >= 3,000/uL
- Absolute neutrophil count >= 1,500/uL
- Hemoglobin >= 9.0 gm/dL
- Platelets >= 100,000/uL
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN)
- Creatinine within normal institutional limits, OR creatinine clearance >= 60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal
- Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A female of childbearing potential is defined of one who is biologically capable of becoming pregnant. Reliable contraception should be used starting from trial screening and must be continued throughout the study
- Females of childbearing potential must agree to use effective contraceptive method starting with the first dose of study therapy through 6 months after the last dose of study therapy
- Male participants must agree to use an effective method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy
- Participants must read, have the ability to understand, agree to, and sign a statement of Informed Consent prior to participation in this study
Participants must, as part of their planned treatment per institutional guidelines, be:
- Scheduled to receive preoperative FOLFOX or CAPOX chemotherapy, which requires a central venous access device for administration
- Able to undergo planned TME of the rectal tumor per institutional standards
Exclusion Criteria:
- Recurrent rectal cancer
- Primary unresectable rectal cancer. A tumor is considered unresectable when invading adjacent organs (T4b disease) and an en bloc resection will not achieve negative margins. Rectal cancer presenting with concurrent or overlapping sites in the colon is eligible if these sites could be removed with surgery
- Distant nodal disease (retroperitoneal nodes), or any metastatic disease by computed tomography (CT) or positron emission tomography (PET)
- Creatinine > 1.5 x ULN
- History of peripheral neuropathy > grade 2
- History of malabsorption syndromes or inflammatory bowel disease
- Use of immunosuppressive or myelosuppressive medications including but not limited to adalimumab, azathioprine, BCG, clozapine, cyclosporine, deferiprone, etanercept, fingolimod, hydroxyurea, interferon, leflunomide, methotrexate, mycophenolate, natalizumab, pimecrolimus, rituximab, sirolimus, and tacrolimus
- Inability to take oral medications
- Participants who received prior pelvic radiotherapy
- Use of induction chemotherapy prior to chemo-radiation of rectal cancer
- Use of other chemotherapy regimens other than FOLFOX or CAPOX
- Participants who are unable to undergo an MRI
- Participants who are unable to undergo TME
- Refusal of standard-of-care TME of the rectal tumor if there is persistent disease after neoadjuvant treatment
- Participants with a history of any arterial thrombotic event within the past 6 months, including angina (stable or unstable), myocardial infarction (MI), transient ischemic attack (TIA), or cerebrovascular accident (CVA)
- Participants with a recent history of venous thrombotic episodes such as deep venous thrombosis and pulmonary embolism within the past 3 months. If these episodes occurred more than three months prior to enrollment, they may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Similarly, participants who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy
- Febrile illness within 7 days of study enrollment
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102 or other agents used in this study
- Other anticancer or experimental therapy. No other experimental therapies including for other disease indications are allowed while the participant is receiving study treatment
- Women who are pregnant or breast-feeding
- Participants with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study
- Participants with a history of a prior malignancy within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (TAS-102, IMRT, 3D-CRT)
Patients receive TAS-102 PO BID Monday-Friday on weeks 1, 3, and 5. Patients also undergo IMRT or 3D-CRT 5 days per week on weeks 1-5.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients then undergo standard of care FOLFOX or CAPOX.
|
Undergo IMRT
Other Names:
Undergo 3D-CRT
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of dose limiting toxicity (DLT)s for TAS-102 at the maximum tolerated dose (MTD)
Time Frame: Up to end of week 8, or start of fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or capecitabine/oxaliplatin (CAPOX) chemotherapy, whichever occurs first
|
Will be assessed through the Bayesian optimal interval design and will be determined by the proportion of grade 3 or higher adverse events during chemo-radiation therapy (CRT) with TAS-102 at the MTD by allowing no more than 30% DLT.
The proportion will be descriptively noted.
|
Up to end of week 8, or start of fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or capecitabine/oxaliplatin (CAPOX) chemotherapy, whichever occurs first
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events (AEs) (all grade) for TAS-102 concurrent with radiation therapy (RT)
Time Frame: Up to start of FOLFOX or CAPOX (up to 8 weeks)
|
Descriptive statistics of safety will be presented using National cancer Institute Common Terminology Criteria for Adverse Events version 5.0., with AEs tabulated by the MedDRA preferred term and system organ class.
The incidence of AEs (all grades) for TAS-102 with concurrent RT will be assessed using the CRT analysis set.
|
Up to start of FOLFOX or CAPOX (up to 8 weeks)
|
Incidence of grade 3 or higher treatment emergent adverse events (TEAEs) during FOLFOX or CAPOX treatment
Time Frame: Up to end of FOLFOX or CAPOX (up to 16 weeks)
|
The incidence of grade 3 or higher TEAEs during FOLFOX or CAPOX chemotherapy will be assessed using the FOLFOX/CAPOX analysis set.
|
Up to end of FOLFOX or CAPOX (up to 16 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of complete response (CR) by magnetic resonance imaging (MRI) after chemo-radiation therapy (CRT)
Time Frame: Prior to starting FOLFOX or CAPOX regimen (up to 8 weeks)
|
MRI report after CRT will be collected from medical records.
Discrepancies will be resolved with the diagnostic radiology investigators of the research team.
Complete response based on MRI will be tabulated as proportions and analyzed descriptively using the CRT analysis sets.
|
Prior to starting FOLFOX or CAPOX regimen (up to 8 weeks)
|
Rate of CR by endoscopic exam after CRT
Time Frame: Prior to starting FOLFOX or CAPOX regimen (up to 8 weeks)
|
Endoscopic exam report after CRT will be collected from medical records (as available).
Discrepancies will be resolved with the surgical oncology investigators of the research team.
Complete response based on endoscopic exam will be tabulated as proportions and analyzed descriptively using the CRT analysis sets.
|
Prior to starting FOLFOX or CAPOX regimen (up to 8 weeks)
|
Rate of clinical complete response (cCR) by MRI and endoscopic response after CRT
Time Frame: Prior to starting FOLFOX or CAPOX regimen (up to 8 weeks)
|
cCR requires CR for MRI and CR for endoscopic responses.
The number of cCR after CRT will be tabulated as proportions using the CRT analysis sets, respectively.
|
Prior to starting FOLFOX or CAPOX regimen (up to 8 weeks)
|
Rate of CR by MRI after CRT and FOLFOX or CAPOX
Time Frame: At end of chemotherapy visit (up to 21 weeks)
|
MRI report after CRT + FOLFOX or CAPOX will be collected from medical records.
Discrepancies will be resolved with the diagnostic radiology investigators of the research team.
Complete response based on MRI will be tabulated as proportions and analyzed descriptively using the CRT and the FOLFOX/CAPOX analysis sets, respectively.
|
At end of chemotherapy visit (up to 21 weeks)
|
Rate of CR by endoscopic exam after CRT and FOLFOX or CAPOX
Time Frame: At end of chemotherapy visit (up to 21 weeks)
|
Endoscopic exam report after CRT + FOLFOX or CAPOX will be collected from medical records (as available).
Discrepancies will be resolved with the surgical oncology investigators of the research team.
Complete response based on endoscopic exam will be tabulated as proportions and analyzed descriptively using the CRT and the FOLFOX/CAPOX analysis sets, respectively.
|
At end of chemotherapy visit (up to 21 weeks)
|
Rate of cCR by MRI and endoscopic response after CRT and FOLFOX or CAPOX
Time Frame: At end of chemotherapy visit (up to 21 weeks)
|
cCR requires CR for MRI and CR for endoscopic responses.
The number of cCR after CRT and after CRT + FOLFOX or CAPOX will be tabulated as proportions using the CRT and the FOLFOX/CAPOX analysis sets, respectively.
|
At end of chemotherapy visit (up to 21 weeks)
|
Rate of pathologic complete response after standard total mesorectal excision (TME)
Time Frame: At resection (up to 29 weeks)
|
Pathology report after standard TME will be collected from medical records.
Discrepancies will be resolved with the surgical oncology and pathology investigators of the research team.
Complete response based on pathology will be tabulated as proportions and analyzed descriptively using the TME population.
|
At resection (up to 29 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charles D Lopez, MD, PhD, OHSU Knight Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Trifluridine
Other Study ID Numbers
- STUDY00019576 (Other Identifier: OHSU Knight Cancer Institute)
- NCI-2019-06387 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- SOL-19069-L
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage III Rectal Cancer AJCC v8
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedMetastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC... and other conditionsUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingFinancial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing TreatmentStage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IIA Rectal Cancer AJCC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Adenocarcinoma | Advanced Colon Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkActive, not recruitingMetastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterBristol-Myers Squibb; Syntrix Biosystems, Inc.RecruitingMetastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditionsUnited States
Clinical Trials on Intensity-Modulated Radiation Therapy
-
National Cancer Institute (NCI)TerminatedLocally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell CarcinomaUnited States
-
Mount Sinai Hospital, CanadaPrincess Margaret Hospital, CanadaActive, not recruitingAdult Soft Tissue SarcomaCanada, United States, Belgium
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck CarcinomaUnited States
-
Institut Cancerologie de l'OuestCompletedCervical Cancer | Prostate Cancer | Anal Canal CancersFrance
-
Memorial Sloan Kettering Cancer CenterCompletedMetastatic DiseaseUnited States
-
University Health Network, TorontoOntario Cancer Research NetworkCompleted
-
Xiangya Hospital of Central South UniversityRecruitingNasopharyngeal CarcinomaChina
-
Alberta Health servicesCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States